GSK’s Chris Carpenter Joins Rubius as Chief Medical Officer

Xconomy Boston — 

Chris Carpenter has been appointed chief medical officer of Cambridge, MA-based Rubius Therapeutics. Carpenter was most recently senior vice president and head of the cancer epigenetics department at GlaxoSmithKline (NYSE: GSK). His experience also includes posts at Merck (NYSE: MRK) and Harvard Medical School. Earlier this year, Rubius raised $125 million to bring its engineered therapeutic red blood cells into clinical trials.